1-(Thian-4-yl)ethan-1-one | 32358-89-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻烷
• 英文名称: 1-(Thian-4-yl)ethan-1-one
• 英文别名: 1-(thian-4-yl)ethanone
• CAS: 32358-89-7
• 化学式: C₇H₁₂OS
• mdl: MFCD24712022
• 分子量: 144.24
• InChiKey: DTDVABNLQCBXLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20130324529A1

  公开（公告）日：2013-12-05

  The present invention is related to novel benzimidazole compounds of formula (I) having cannabinoid receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, in particular humans.

  本发明涉及具有大麻素受体激动性质的新型苯并咪唑化合物（I）的公式，包括这些化合物的药物组合物，制备这些化合物的化学过程以及它们在治疗与大麻素受体在动物中介导相关的疾病，特别是人类中的用途。
• [EN] SPIROINDOLINE DERIVATIVES AS GONADOTROPIN- RELEASING HORMONE RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE LA SPIROINDOLINE COMME ANTAGONISTES DU RÉCEPTEUR DE L'HORMONE LIBÉRANT LA GONATROPHINE (GNRH)
  申请人：BAYER IP GMBH

  公开号：WO2013107743A1

  公开（公告）日：2013-07-25

  Spiroindoline derivatives, process for their preparation and pharmaceutical compositions thereof, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selded from the group of endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reprodudive therapy such as in vitro fertilization). The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.

  螺环吲哚衍生物，其制备方法和药物组合物，用于治疗和/或预防疾病，以及用于制造用于治疗和/或预防疾病的药物，特别是男性和女性的性激素相关疾病，尤其是来自子宫内膜异位症、子宫肌瘤、多囊卵巢综合征、多毛症、早熟、依赖性生殖腺类固醇的肿瘤如前列腺、乳腺和卵巢癌、促性腺激素垂体腺瘤、睡眠呼吸暂停、肠易激综合征、经前综合征、良性前列腺增生、避孕和不孕（例如辅助生殖治疗如体外受精）。本申请特别涉及螺环吲哚衍生物作为促性腺激素释放激素（GnRH）受体拮抗剂。
• Thiazole derivatives
  申请人：Nakajima Takao

  公开号：US20070105919A1

  公开（公告）日：2007-05-10

  (Wherein n is an integer of from 0 to 3; R 1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group; R 2 is halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, —COR 8 , or the like; R 3 and R 4 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, —COR 12 , or the like) For example, provided are adenosine A 2A receptor antagonists comprising, as the active ingredient, a thiazole derivative represented by a general formula (I), or a pharmaceutically acceptable salt thereof, and the like.

  其中n为0至3的整数；R1代表取代或未取代的环烷基、取代或未取代的芳基、取代或未取代的脂环杂环基或取代或未取代的芳香杂环基；R2代表卤素、取代或未取代的低碳基、取代或未取代的芳基、取代或未取代的脂环杂环基、取代或未取代的芳香杂环基、-COR8或类似物；R3和R4可以相同也可以不同，每个代表氢原子、取代或未取代的低碳基、取代或未取代的芳基烷基、-COR12或类似物。例如，提供了包含噻唑衍生物的腺苷A2A受体拮抗剂作为活性成分，其表示为通式（I）或其药学上可接受的盐等。
• THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER
  申请人：Uesaka Noriaki

  公开号：US20100152162A1

  公开（公告）日：2010-06-17

  It is intended to provide an agent for treating and/or preventing sleep disorder containing as an active ingredient a thiazole derivative represented by the general formula (I) (in the formula, R 1 represents a five-membered aromatic heterocyclic group containing at least one oxygen atom or the like, R 2 represents halogen or the like, and R 3 represents —NR 10 R 11 (in the formula, R 10 and R 11 are the same or different and represent a hydrogen atom or the like) or the like) or a pharmacologically acceptable salt thereof.

  该发明旨在提供一种治疗和/或预防睡眠障碍的药剂，其活性成分为一种由通式（I）表示的噻唑衍生物（在公式中，R1表示至少含有一个氧原子的五元芳香杂环基团或类似基团，R2表示卤素或类似基团，R3表示-NR10R11（在公式中，R10和R11相同或不同，表示氢原子或类似基团）或类似基团）或其药理学上可接受的盐。
• THIAZOLE DERIVATIVES
  申请人：Nakajima Takao

  公开号：US20100256361A1

  公开（公告）日：2010-10-07

  (Wherein n is an integer of from 0 to 3; R 1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group; R 2 is halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, —COR 8 , or the like; R 3 and R 4 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, —COR 12 , or the like) For example, provided are adenosine A 2A receptor antagonists comprising, as the active ingredient, a thiazole derivative represented by a general formula (I), or a pharmaceutically acceptable salt thereof, and the like.

  其中n是0至3的整数；R1是取代或未取代的环烷基、取代或未取代的芳基、取代或未取代的脂环杂环基或取代或未取代的芳香杂环基；R2是卤素、取代或未取代的低碳基、取代或未取代的芳基、取代或未取代的脂环杂环基、取代或未取代的芳香杂环基、-COR8等；R3和R4可以相同也可以不同，每个代表氢原子、取代或未取代的低碳基、取代或未取代的芳基、取代或未取代的芳基烷基、-COR12等。例如，提供了含有噻唑衍生物的腺苷A2A受体拮抗剂，作为活性成分，其表示为通式（I）或其药学上可接受的盐等。